Gene therapies have huge potential in the field of rare disease. The fact that these therapies could offer a potential cure otherwise fatal diseases has given families incredible hope. Unfortunately,…
According to a story from finanznachrichten.de, the latest data from three phase 3 studies is giving further confirmation to the capability of the recently approved gene therapy Zolgensma to have…
Happy Thursday everyone! This week, we're sharing a video that will warm your heart, as well as an article about how to improve care in older Multiple Myeloma patients. We…
According to the American Journal of Managed Care (AJMC), the US Food and Drug Administration (USFDA) has approved Pexidartinib (Turalio) drug as first targeted therapy to treat symptomatic Tenosynovial Giant…
According to a story from sectorpublishingintelligence.co.uk, the drug company INVENTIVA's lead product candidate, known as lanifibranor, has earned Fast Track Designation from the US Food and Drug Administration (FDA) as…
-150x150.jpg)
Pamela Smith, age 67, had run out of options when her melanoma metastasized and became inoperable. According to a recent article in MedicalXpress, in January 2014, Pamela joined the…
Happy Thursday everyone! This week, we're highlights two stories about patients taking action to solve problems in their life: one patient innovates to improve their care, and another starts a…
According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
